BIONTECH SE SPON. ADRS 1
Commented by Stefan Feulner on May 23rd, 2022 | 13:01 CEST
BioNTech, Monkeypox, Defence Therapeutics, Valneva - Is the next threat coming after Corona?
The Corona pandemic is not over yet, but we should already prepare for future viruses. The next pandemic will come. When it will come is uncertain, and so is which pathogen will we have to deal with. Monkeypox is now spreading globally, and there are already the first cases in Germany. We find out what is known so far, where the dangers lie and what opportunities there are for the biotechnology sector from Dr Moutih Rafei, a renowned pharmacologist and head of research and development at the innovative company Defence Therapeutics Inc.
Read
Commented by Fabian Lorenz on May 19th, 2022 | 13:31 CEST
Booster for the BioNTech share: BASF and Defense Metals with momentum?
The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.
Read
Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST
Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!
For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?
Read
Commented by Carsten Mainitz on May 17th, 2022 | 13:11 CEST
BioNTech, mm2 Asia, TUI - Do not oversleep!
At least in Europe, "normality" seems to have set in in everyday life - that is, concerning Corona. However, cautionary voices are already pointing to the winter season and the associated threat of new mutations. Nevertheless, given the Ukraine war and the major security-political tensions in the world, nothing is "normal." Investors should be vigilant in following geopolitical developments and not miss out on the opportunities that continually present themselves at the corporate level.
Read
Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST
BioNTech, BYD and Desert Gold: Shares for the rebound
Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.
Read
Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST
Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology
Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.
Read
Commented by Nico Popp on May 5th, 2022 | 11:52 CEST
Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva
Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.
Read
Commented by Fabian Lorenz on May 3rd, 2022 | 11:48 CEST
BYD and Altech with strong news: Hope for BioNTech shares?
Rising interest rates, the war in Ukraine, lockdowns in China and recession fears: the current global mix is not conducive to rising share prices, but there is also positive news from companies. Among them is BYD. The largest Chinese manufacturer of electric cars has published quarterly figures and thus convinced analysts. In addition, BYD is celebrating the delivery anniversary of its flagship. The share of Altech Advanced Materials is also currently stepping on the gas. A study has confirmed that the planned production plant of the Heidelberg-based Company can be highly profitable. With the plant, Altech wants to stir up the market for lithium-ion batteries. BioNTech shareholders are still waiting for positive news - but there is hope.
Read
Commented by André Will-Laudien on May 2nd, 2022 | 13:27 CEST
BioNTech, Defence Therapeutics, Valneva, MorphoSys - Biotech stocks that will still be fun tomorrow!
One of the most churned areas on the growth stock market is the biotech sector. There was too much disappointment on the drug development side; even in the COVID sector, only a few winners remain. However, the current sell-off could turn out to be an entry opportunity in the medium term because there are more and more people on earth and, fortunately, they are getting older and older; even the Corona pandemic is not likely to change this. There are already 1 billion people worldwide over the age of 60, and forecasts predict that this figure will rise to 2 billion by 2050 - with a total population of more than 9 billion people predicted at that time. Which values have been unjustly neglected, and where are the current opportunities for investors?
Read
Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST
BioNTech, NervGen, Sanofi - The rebound is on the way
Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.
Read